Education
About Us
Working with TipRanks
Follow Us
Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
CRVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.54 - $10.00
Previous CloseN/A
Volume202.27K
Average Volume (3M)825.80K
Market Cap
$321.57M
Enterprise Value$195.93M
Total Cash (Recent Filing)$44.21M
Total Debt (Recent Filing)$1.15M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 12, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding77,114,640
10 Day Avg. Volume464,096
30 Day Avg. Volume825,804
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.33K
Enterprise Value/Ebitda-6.29
Forecast
1Y Price Target
$13.00Price Target Upside217.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Drug EfficacyThe latest update showed that 63% of patients treated with the 200 mg BID dose achieved EASI 75, outperforming placebo benchmarks.
Future OpportunitiesPositive data in atopic dermatitis could open opportunities for soquelitinib in other immune diseases, potentially boosting CRVS shares.
Therapeutic PotentialAnalysts believe that soquelitinib could become one of the best AD therapies on the market based on the results from the latest patient cohort.
Bears Say
Financial PerformanceThe company reported no revenues and a net loss of $0.13 per diluted share, compared to consensus estimated net loss of $0.12 per share.
Investor ConfidenceThere is a lack of investor confidence that higher dose data will show improved results, contributing to the stock's decline.
Market CompetitionThe significant drop in CRVS shares is seen as an overreaction, potentially due to market disappointment with soquel's efficacy compared to Dupixent.
Corvus Pharmaceuticals News
CRVS FAQ
What was Corvus Pharmaceuticals Inc’s price range in the past 12 months?
Corvus Pharmaceuticals Inc lowest stock price was $2.54 and its highest was $10.00 in the past 12 months.
What is Corvus Pharmaceuticals Inc’s market cap?
Corvus Pharmaceuticals Inc’s market cap is $321.57M.
When is Corvus Pharmaceuticals Inc’s upcoming earnings report date?
Corvus Pharmaceuticals Inc’s upcoming earnings report date is Aug 12, 2025 which is in 9 days.
How were Corvus Pharmaceuticals Inc’s earnings last quarter?
Corvus Pharmaceuticals Inc released its earnings results on May 08, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.01.
Is Corvus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Corvus Pharmaceuticals Inc’s price is currently Undervalued.
Does Corvus Pharmaceuticals Inc pay dividends?
Corvus Pharmaceuticals Inc does not currently pay dividends.
What is Corvus Pharmaceuticals Inc’s EPS estimate?
Corvus Pharmaceuticals Inc’s EPS estimate is -0.13.
How many shares outstanding does Corvus Pharmaceuticals Inc have?
Corvus Pharmaceuticals Inc has 77,114,640 shares outstanding.
What happened to Corvus Pharmaceuticals Inc’s price movement after its last earnings report?
Corvus Pharmaceuticals Inc reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went up 32.239%.
Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in CRVS
Corvus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (217.07% Upside)
$13.00 (217.07% Upside)
Blogger Sentiment
Neutral
CRVS Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 963.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
62.25%
12-Months-Change
Fundamentals
Return on Equity
-100.13%
Trailing 12-Months
Asset Growth
48.28%
Trailing 12-Months
Company Description
Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
CRVS Company Deck
CRVS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for Corvus Pharmaceuticals, with significant net income growth, successful warrant exercises boosting cash position, and promising Phase 1 trial results for soquelitinib. Despite the increase in R&D expenses and a decrease in cash reserves, the company's financial position remains robust, supported by the recent warrant exercise.Read More>CRVS Stock 12 Month Forecast
Average Price Target
$13.00
▲(217.07%Upside)
Technical Analysis
Ownership Overview
22.20% Insiders
4.04% Mutual Funds
0.21% Other Institutional Investors
66.74% Public Companies and
Individual Investors